Cancer Prevention Pharmaceuticals, Inc. - FORM S-1/A - EX-23.3 - EXHIBIT 23.3 - February 2, 2016

Attached files

file filename
EX-3.5 - EXHIBIT 3.5 - Cancer Prevention Pharmaceuticals, Inc.v428858_ex3-5.htm
EX-1.1 - EXHIBIT 1.1 - Cancer Prevention Pharmaceuticals, Inc.v428858_ex1-1.htm
EX-3.6 - EXHIBIT 3.6 - Cancer Prevention Pharmaceuticals, Inc.v428858_ex3-6.htm
EX-5.1 - EXHIBIT 5.1 - Cancer Prevention Pharmaceuticals, Inc.v428858_ex5-1.htm
EX-3.7 - EXHIBIT 3.7 - Cancer Prevention Pharmaceuticals, Inc.v428858_ex3-7.htm
EX-4.15 - EXHIBIT 4.15 - Cancer Prevention Pharmaceuticals, Inc.v428858_ex4-15.htm
EX-23.1 - EXHIBIT 23.1 - Cancer Prevention Pharmaceuticals, Inc.v428858_ex23-1.htm
EX-4.18 - EXHIBIT 4.18 - Cancer Prevention Pharmaceuticals, Inc.v428858_ex4-18.htm
EX-4.19 - EXHIBIT 4.19 - Cancer Prevention Pharmaceuticals, Inc.v428858_ex4-19.htm
EX-4.10 - EXHIBIT 4.10 - Cancer Prevention Pharmaceuticals, Inc.v428858_ex4-10.htm
EX-4.16 - EXHIBIT 4.16 - Cancer Prevention Pharmaceuticals, Inc.v428858_ex4-16.htm
EX-4.17 - EXHIBIT 4.17 - Cancer Prevention Pharmaceuticals, Inc.v428858_ex4-17.htm
EX-4.11 - EXHIBIT 4.11 - Cancer Prevention Pharmaceuticals, Inc.v428858_ex4-11.htm
EX-10.34 - EXHIBIT 10.34 - Cancer Prevention Pharmaceuticals, Inc.v428858_ex10-34.htm
EX-10.29 - EXHIBIT 10.29 - Cancer Prevention Pharmaceuticals, Inc.v428858_ex10-29.htm
EX-10.32 - EXHIBIT 10.32 - Cancer Prevention Pharmaceuticals, Inc.v428858_ex10-32.htm
EX-10.30 - EXHIBIT 10.30 - Cancer Prevention Pharmaceuticals, Inc.v428858_ex10-30.htm
EX-10.31 - EXHIBIT 10.31 - Cancer Prevention Pharmaceuticals, Inc.v428858_ex10-31.htm
S-1/A - FORM S-1/A - Cancer Prevention Pharmaceuticals, Inc.v428858_s1a.htm
EX-10.33 - EXHIBIT 10.33 - Cancer Prevention Pharmaceuticals, Inc.v428858_ex10-33.htm

 

Exhibit 23.3

 

 

Re: Consent of GfK (f/k/a Bridgehead International)

 

  To Whom It May Concern:

 

1 February 2016

 

Arthur F. Kuhn

Vice President

Business Support

484.441.1891

arthur.kuhn@gfk.com

   We hereby consent to (1) the use of and all references to the name of Bridgehead International in the prospectus included, in the registration statement on Form S-1 of Cancer Prevention Pharmaceuticals, Inc. (the “Company”) and any amendments thereto (the “Registration Statement”); including, but not limited to, the use of the information supplied by us and set forth under the “Prospectus Summary” and  “Business” sections; and (2) the filing of this consent as an exhibit to the Registration Statement by the Company for the use of our data and information cited in the above- mentioned sections of the Registration Statement.

 

  Sincerely,  
     
  /s/ Arthur Kuhn  
  Arthur Kuhn  
  Vice President, Business Support  

 

GfK Custom Research, LLC  
1275 Drummers Lane, Suite 300  
Wayne, PA 19087  
USA  
   
Tel. 484.441.1700  
Fax 610.566.9189